In Brief: OTC emergency eyewash meeting, FDA official to Perrigo, e-cigarette regulation urged, emerging markets key for J&J in OTC
This article was originally published in The Tan Sheet
Executive Summary
FDA seeks OTC emergency eyewash input; CDER office head moves to Perrigo; Lawmakers, medical groups urge e-cigarette regulation; J&J eyes emerging markets for OTC business; more news In Brief.
You may also be interested in...
Jenkins' Retirement From US FDA Was Several Years In The Making
Outgoing Office of New Drugs director dismisses speculation that his decision to leave the agency was related to events surrounding Sarepta's controversial Exondys 51 approval.
J&J Prioritizes OTC Return With McNeil Remediation End In Sight
Johnson & Johnson CEO Alex Gorsky says bringing recalled OTCs such as Tylenol and Motrin products back to market is the firm’s “clear number one priority” in the near term. J&J also has a timetable for completing its responsibilities under a consent decree with FDA in place since 2011.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.